tert-Butyl 2-(8-oxo-7,8-dihydropyrazino[2,3-d]pyridazin-5-yl)acetate

Catalog No. :
ACZFBO271
CAS No. :
1355612-95-1
Molecular Formula :
C12H14N4O3
Molecular Weight :
262.27

IUPAC Name:tert-butyl 2-(8-oxo-7,8-dihydropyrazino[2,3-d]pyridazin-5-yl)acetate

tert-Butyl 2-(8-oxo-7,8-dihydropyrazino[2,3-d]pyridazin-5-yl)acetate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25g98%$104.00Login to see priceIn stockInquiry
100g98%$342.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 2-(8-oxo-7,8-dihydropyrazino[2,3-d]pyridazin-5-yl)acetate
IUPAC Nametert-butyl 2-(8-oxo-7,8-dihydropyrazino[2,3-d]pyridazin-5-yl)acetate
MDL No.MFCD35057994
Molecular FormulaC12H14N4O3
Molecular Weight262.27
SMILESO=C1NN=C(CC(OC(C)(C)C)=O)C2=C1N=CC=N2
InChI KeyUCEQBWWCTJMMBN-UHFFFAOYSA-N
Synonymtert-butyl 2-(8-oxo-7,8-dihydropyrazino[2,3-d]pyridazin-5-yl)acetate;tert-butyl 2-(5-oxo-5,6-dihydropyrido[3,4-b]pyrazin-8-yl)acetate;Pyrazino[2,3-d]pyridazine-5-acetic acid, 7,8-dihydro-8-oxo-, 1,1-dimethylethyl ester
CAS No.1355612-95-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACZFBO271 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACZFBO271 route product structure diagram
    ACZFBO2711355612-95-1 In Stock
Inquiry

2. ACZFBO271 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZFBO271 route product structure diagram
    ACZFBO2711355612-95-1 In Stock
Inquiry

Comments (0)